Sandoz launches authorized versions of Cozaar® and Hyzaar® tablets

Sandoz launches authorized versions of Cozaar® and Hyzaar® tablets

Princeton, NJ, April 7, 2010 -Sandoz Inc. announced today the introduction in the US of losartan potassium and losartan potassium-hydrochlorothiazide (HCTZ) tablets, authorized generic equivalents of Merck's Cozaar® and Hyzaar®. Losartan potassium and losartan potassium-HCTZ tablets are intended for the treatment of hypertension.

Sandoz will market losartan potassium in 25mg, 50mg and 100mg strength tablets, and losartan potassium-HCTZ in 50/12.5mg, 100/12.5mg and 100/25mg strength tablets, the same dosage strengths and formulations as Cozaar® and Hyzaar®, respectively.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "risk," or similar expressions, or by express or implied discussions regarding potential future revenues from losartan potassium and losartan potassium HCTZ tablets. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Management's expectations regarding losartan potassium and losartan potassium HCTZ tablets could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected inabilities to obtain or maintain exclusivity periods for our product; competition in general; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz
Sandoz, a Division of the Novartis group, is a global leader in the field of generic pharmaceuticals, offering a wide array of high-quality, affordable products that are no longer protected by patents. Sandoz has a portfolio of about 1000 compounds and sells its products in more than 130 countries. Key product groups include antibiotics, treatments for central nervous system disorders, gastrointestinal medicines, cardiovascular treatments and hormone therapies. Sandoz develops, produces and markets these medicines along with pharmaceutical and biotechnological active substances and anti-infectives. In

 

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.